Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 3/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21176168 | 0.89 | SMN1; SMN2 (0.39) | SMN1; SMN2KDM4CBACE1ROCK2NPC1 | |
| SCHEMBL19974994 | 0.85 | SMN1; SMN2 (0.39) | SMN1; SMN2KDM4CROCK2NPC1RAB9A | |
| SCHEMBL19975407 | 0.83 | ALDH1A1 (0.38) | SMN1; SMN2KDM4CRAB9ACNR1CNR2 | |
| SCHEMBL21176315 | 0.83 | KDM4C (0.38) | SMN1; SMN2KDM4CROCK2NPC1RAB9A | |
| SCHEMBL21176203 | 0.80 | KDM4C (0.39) | SMN1; SMN2KDM4CROCK2NPC1RAB9A | |
| SCHEMBL19975438 | 0.77 | SMN1; SMN2 (0.43) | SMN1; SMN2KDM4CNPC1RAB9AALDH1A1 | |
| SCHEMBL21176297 | 0.74 | SMYD3 (0.43) | SMN1; SMN2KDM4CBACE1ROCK2CNR1 | |
| SCHEMBL19975370 | 0.73 | PTGIR (0.40) | ALDH1A1BCHE | |
| SCHEMBL21176169 | 0.72 | SMYD3 (0.45) | SMN1; SMN2KDM4CROCK2CNR1CNR2 | |
| SCHEMBL19975245 | 0.71 | ADH1A (0.42) | SMN1; SMN2ALDH1A1GAAL3MBTL1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2022-11-10 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | PLA2G1B, PLA2G12A, PLA2G4C | SMN1; SMN2 706/4885KDM4C 3449/4885BACE1 1733/4885 |
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | PLA2G12A, PLA2G1B, PLA2G4C | SMN1; SMN2 1086/4885KDM4C 3887/4885BACE1 2329/4885 |
| US-11091428-B2 | Antiviral compounds | PLA2G1B, PLA2G12A, PLA2G4C | SMN1; SMN2 706/4885KDM4C 3449/4885BACE1 1733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.